Cargando…

Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis

SIMPLE SUMMARY: The diagnosis and risk stratification of prostate cancer (PCa) is associated with difficulties for both the examiner and the patient: the tumor burden and the aggressiveness of the tumor should be determined as accurately as possible without putting too much psychological and physica...

Descripción completa

Detalles Bibliográficos
Autores principales: Krausewitz, Philipp, Kluemper, Niklas, Richter, Ayk-Peter, Büttner, Thomas, Kristiansen, Glen, Ritter, Manuel, Ellinger, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496792/
https://www.ncbi.nlm.nih.gov/pubmed/36139516
http://dx.doi.org/10.3390/cancers14184355
_version_ 1784794356620722176
author Krausewitz, Philipp
Kluemper, Niklas
Richter, Ayk-Peter
Büttner, Thomas
Kristiansen, Glen
Ritter, Manuel
Ellinger, Jörg
author_facet Krausewitz, Philipp
Kluemper, Niklas
Richter, Ayk-Peter
Büttner, Thomas
Kristiansen, Glen
Ritter, Manuel
Ellinger, Jörg
author_sort Krausewitz, Philipp
collection PubMed
description SIMPLE SUMMARY: The diagnosis and risk stratification of prostate cancer (PCa) is associated with difficulties for both the examiner and the patient: the tumor burden and the aggressiveness of the tumor should be determined as accurately as possible without putting too much psychological and physical strain on the patient. The aim of the present proof-of-concept study was to investigate the potential and dynamics of quantitative SEPT9 and SHOX2 methylation, two promising validated non-invasive pan-cancer biomarkers, in PCa patient tissue and circulating cell-free DNA (ccfDNA) during prostate biopsy as a diagnostic tool. SEPT9 and SHOX2 were hypermethylated in PCa tissue and allowed discrimination of disease status, tumor stage and grade. In ccfDNA, methylation of both biomarkers allowed discrimination of localized and metastatic disease and increased shortly after prostate biopsy only in PCa patients. Hence, mSEPT9 and mSHOX2 are promising non-invasive measure in PCa evaluation. ABSTRACT: Background: The methylation status of Septin 9 (SEPT9) and short stature homeobox 2 (SHOX2) in circulating cell-free DNA (ccfDNA) are validated pan-cancer biomarkers. The present proof-of-concept study aimed to investigate the potential and dynamics of quantitative SEPT9 and SHOX2 methylation in prostate cancer (PCa) patient tissue and ccfDNA during prostate biopsy as a diagnostic tool. Methods: The methylation patterns of SEPT9 and SHOX2 in prostate tissue were analyzed using The Cancer Genome Atlas data set (n = 498 PCa and n = 50 normal adjacent prostate tissue (NAT)). Next, dynamic changes of ccfDNA methylation were quantified in prospectively enrolled patients undergoing prostate biopsy (n = 72), local treatment for PCa (n = 7; radical prostatectomy and radiotherapy) as well as systemic treatment for PCa (n = 6; chemotherapy and 177-Lu-PSMA-therapy). Biomarker levels were correlated with clinicopathological parameters. Results: SEPT9 and SHOX2 were hypermethylated in PCa tissue (p < 0.001) and allowed discrimination of PCa and non-tumor prostate tissue (mSEPT9: AUC 0.87, 95%CI [0.82–0.92]; mSHOX2: AUC 0.89, 95%CI 0.84–0.94). SHOX2 methylation and mRNA levels were significantly higher in PCa tissue and increased with tumor stage and grade, as well as in patients suffering from biochemical recurrence following radical prostatectomy. SEPT9 and SHOX2 ccfDNA methylation allowed distinguishing patients with localized and metastatic disease (p < 0.001 for both). In addition, methylation levels increased shortly after prostate biopsy only in patients with PCa (ΔmSEPT9: p < 0.001 and ΔmSHOX2: p = 0.001). Conclusions: The early dynamics of methylated SEPT9 and SHOX2 in ccfDNA allow differentiation between PCa patients and patients without PCa and is a promising marker for tumor monitoring in the metastatic stage to determine tumor burden under systemic therapy.
format Online
Article
Text
id pubmed-9496792
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94967922022-09-23 Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis Krausewitz, Philipp Kluemper, Niklas Richter, Ayk-Peter Büttner, Thomas Kristiansen, Glen Ritter, Manuel Ellinger, Jörg Cancers (Basel) Article SIMPLE SUMMARY: The diagnosis and risk stratification of prostate cancer (PCa) is associated with difficulties for both the examiner and the patient: the tumor burden and the aggressiveness of the tumor should be determined as accurately as possible without putting too much psychological and physical strain on the patient. The aim of the present proof-of-concept study was to investigate the potential and dynamics of quantitative SEPT9 and SHOX2 methylation, two promising validated non-invasive pan-cancer biomarkers, in PCa patient tissue and circulating cell-free DNA (ccfDNA) during prostate biopsy as a diagnostic tool. SEPT9 and SHOX2 were hypermethylated in PCa tissue and allowed discrimination of disease status, tumor stage and grade. In ccfDNA, methylation of both biomarkers allowed discrimination of localized and metastatic disease and increased shortly after prostate biopsy only in PCa patients. Hence, mSEPT9 and mSHOX2 are promising non-invasive measure in PCa evaluation. ABSTRACT: Background: The methylation status of Septin 9 (SEPT9) and short stature homeobox 2 (SHOX2) in circulating cell-free DNA (ccfDNA) are validated pan-cancer biomarkers. The present proof-of-concept study aimed to investigate the potential and dynamics of quantitative SEPT9 and SHOX2 methylation in prostate cancer (PCa) patient tissue and ccfDNA during prostate biopsy as a diagnostic tool. Methods: The methylation patterns of SEPT9 and SHOX2 in prostate tissue were analyzed using The Cancer Genome Atlas data set (n = 498 PCa and n = 50 normal adjacent prostate tissue (NAT)). Next, dynamic changes of ccfDNA methylation were quantified in prospectively enrolled patients undergoing prostate biopsy (n = 72), local treatment for PCa (n = 7; radical prostatectomy and radiotherapy) as well as systemic treatment for PCa (n = 6; chemotherapy and 177-Lu-PSMA-therapy). Biomarker levels were correlated with clinicopathological parameters. Results: SEPT9 and SHOX2 were hypermethylated in PCa tissue (p < 0.001) and allowed discrimination of PCa and non-tumor prostate tissue (mSEPT9: AUC 0.87, 95%CI [0.82–0.92]; mSHOX2: AUC 0.89, 95%CI 0.84–0.94). SHOX2 methylation and mRNA levels were significantly higher in PCa tissue and increased with tumor stage and grade, as well as in patients suffering from biochemical recurrence following radical prostatectomy. SEPT9 and SHOX2 ccfDNA methylation allowed distinguishing patients with localized and metastatic disease (p < 0.001 for both). In addition, methylation levels increased shortly after prostate biopsy only in patients with PCa (ΔmSEPT9: p < 0.001 and ΔmSHOX2: p = 0.001). Conclusions: The early dynamics of methylated SEPT9 and SHOX2 in ccfDNA allow differentiation between PCa patients and patients without PCa and is a promising marker for tumor monitoring in the metastatic stage to determine tumor burden under systemic therapy. MDPI 2022-09-07 /pmc/articles/PMC9496792/ /pubmed/36139516 http://dx.doi.org/10.3390/cancers14184355 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Krausewitz, Philipp
Kluemper, Niklas
Richter, Ayk-Peter
Büttner, Thomas
Kristiansen, Glen
Ritter, Manuel
Ellinger, Jörg
Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis
title Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis
title_full Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis
title_fullStr Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis
title_full_unstemmed Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis
title_short Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis
title_sort early dynamics of quantitative sept9 and shox2 methylation in circulating cell-free plasma dna during prostate biopsy for prostate cancer diagnosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496792/
https://www.ncbi.nlm.nih.gov/pubmed/36139516
http://dx.doi.org/10.3390/cancers14184355
work_keys_str_mv AT krausewitzphilipp earlydynamicsofquantitativesept9andshox2methylationincirculatingcellfreeplasmadnaduringprostatebiopsyforprostatecancerdiagnosis
AT kluemperniklas earlydynamicsofquantitativesept9andshox2methylationincirculatingcellfreeplasmadnaduringprostatebiopsyforprostatecancerdiagnosis
AT richteraykpeter earlydynamicsofquantitativesept9andshox2methylationincirculatingcellfreeplasmadnaduringprostatebiopsyforprostatecancerdiagnosis
AT buttnerthomas earlydynamicsofquantitativesept9andshox2methylationincirculatingcellfreeplasmadnaduringprostatebiopsyforprostatecancerdiagnosis
AT kristiansenglen earlydynamicsofquantitativesept9andshox2methylationincirculatingcellfreeplasmadnaduringprostatebiopsyforprostatecancerdiagnosis
AT rittermanuel earlydynamicsofquantitativesept9andshox2methylationincirculatingcellfreeplasmadnaduringprostatebiopsyforprostatecancerdiagnosis
AT ellingerjorg earlydynamicsofquantitativesept9andshox2methylationincirculatingcellfreeplasmadnaduringprostatebiopsyforprostatecancerdiagnosis